Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
A phase 2 trial of Domvanalimab, Zimberelimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Arcus Biosciences, Inc., active and no longer recruiting.
Overview
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer is a phase 2 interventional study registered as NCT04736173 by Arcus Biosciences, Inc., with 169 participants enrolled, started 2021-02-08 and due to reach its primary completion in 2027-05. Interventions recorded: Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed. Conditions listed: Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Novel Treatment Combinations in Patients With Lung Cancer
Shares Domvanalimab, Zimberelimab, Pemetrexed, Carboplatin.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Domvanalimab, Zimberelimab, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.